Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Thursday, May 10, 2018

FDA Cautions About Risks of Coiling for Brain Aneurysms

Did gluing fall by the wayside? Be careful out there.
I guess this is why gluing is not done:
FDA issues warning about Covidien brain device that has killed nine - Onyx glue
Maybe this instead:

Startup tests mesh+microsponges as alternative brain aneurysm treatment

But don't listen to me I have no medical training. 

FDA Cautions About Risks of Coiling for Brain Aneurysms

Procedural risks, patient selection should be considered

  • by Nicole Lou,
Reporter, MedPage Today/
WASHINGTON -- After reports of periprocedural stroke and death with the use of neurovascular stents for stent-assisted coiling (SAC), the FDA issued a safety alert with recommendations for safe use of these devices in the treatment of unruptured brain aneurysms.
Reports received of periprocedural stroke and death may have been related to procedural risks or poor patient selection, the FDA determined.

"Neurovascular stents for SAC provide important options for the treatment of wide-neck brain aneurysms, and their technology continues to evolve. However, these procedures are not without risks, and careful patient selection and proper device use are critical to ensure that the benefits to the patient outweigh the risk of treatment. Many patients with unruptured brain aneurysms can be managed conservatively with routine monitoring and follow-up depending on their individual risk factors for aneurysm rupture," wrote the FDA's William Maisel, MD, MPH, in the letter to healthcare providers.
In smaller brain aneurysms or in patients with reduced life expectancy, the risks of endovascular coiling may outweigh their benefits, the agency noted. Operators should also be aware that neurovascular stents are only approved for certain brain aneurysms, and that they should avoid use of these devices in patients who cannot take systemic anticoagulant or antiplatelet drugs.

No comments:

Post a Comment